THE NOMINATION COMMITTEE’S PROPOSALS TO THE ANNUAL GENERAL MEETING IN KARO PHARMA AB (PUBL)
STOCKHOLM, 9 May 2016 – The Nomination Committee of Karo Pharma AB (publ) has informed the company of its proposals to the annual general meeting 2016.
Prior to the annual general meeting 2016, the Nomination Committee has consisted of Anders Lönner (chairman), chairman of the board, representing own holdings, Hans Ek, representing (SEB Investment Management), Leif Edlund, representing Johan Edlund and Per-Anders Johansson, representing own holdings (Nomic AB). Anders Lönner has been elected chairman of the Nomination Committee.
The nomination committee proposes election of four ordinary board members elected by the annual general meeting and no deputy members.
The nomination committee proposes re-election of the board members Anders Lönner, Thomas Hedner, Per-Anders Johansson and Jean Lycke. Göran Wessman has declined re-election. Anders Lönner is proposed to be elected chairman of the board.
The Nomination Committee is of the opinion that the remuneration to the board should remain unchanged and be paid by SEK 420,000 to the chairman and SEK 150,000 to each of the other directors.
The Nomination Committee further proposes re-election of the accounting firm PricewaterhouseCoopers AB and that remuneration to the auditor be paid as per approved invoice.
The chairman of the board Anders Lönner is proposed to be chairman of the meeting.
The Nomination Committee’s reasoned statement on its proposals to the annual general meeting will be published on the company’s website as soon as it is received by the company.
For further information, please contact:
Henrik Palm, CFO, email henrik.palm@karopharma.se, telephone +46 70 540 4014
About Karo Pharma
Karo Pharma is a health care company focused on developing and marketing of products to pharmacies, fast-moving consumer goods and the health care directly. Karo Pharma is listed on Nasdaq Stockholm.
Karo Pharma publishes this information according to the Swedish Securities Market Act. The information was submitted for publication on 9 May 2016, at 8.30 a.m. CET.
This press release is also available at www.karopharma.se and www.newsroom.cision.com
Tags: